Arovella Therapeutics (ALA) Corporate presentation summary
Event summary combining transcript, slides, and related documents.
Corporate presentation summary
6 Jul, 2026Investment highlights
U.S. FDA IND accepted for ALA-101, with phase 1 trials for CD19-positive blood cancers expected in FY2026.
Developing off-the-shelf iNKT cell therapies for blood and solid tumour cancers.
Proprietary, clinic-ready manufacturing process for CAR-iNKT cells established.
Strategic acquisitions and strong leadership with cell therapy expertise.
Financial overview
Market capitalisation of $88.24 million as of May 2026, with $16.6 million cash on hand at March 2026.
Share price ranged from $0.067 to $0.115 over the past year.
Major shareholders include UBS Nominees and Netwealth Investments.
Leadership and advisory network
Senior management and board have extensive drug development backgrounds.
Scientific and clinical advisory boards include experts from leading cancer centers globally.
Latest events from Arovella Therapeutics
- ALA-101 reached clinical readiness as cash runway stood at 4.2 quarters.ALA
Q1 2027 TU - Off-the-shelf CAR-INKT platform advances toward clinical validation and broader indications.ALACorporate presentation
- An off-the-shelf CAR-INKT platform targets blood cancers, solid tumors and autoimmunity.ALAInvestor presentation
- Scalable CAR-iNKT platform advances to clinical trials, targeting cancer and autoimmune markets.ALACorporate presentation
- Advanced lead cell therapy to Phase 1 trials, narrowing net loss and maintaining strong cash reserves.ALAH2 2026
- Off-the-shelf CAR-iNKT therapies advance to clinical trials, targeting broad oncology and autoimmune markets.ALAInvestor update
- FDA IND accepted for ALA-101, advancing off-the-shelf iNKT cell therapies for cancer.ALACorporate presentation
- IND clearance and strong cash position support clinical trial launch for lead cell therapy.ALAQ3 2026 TU
- Net loss narrowed 14% to $7.5M as revenue rose 700% and cash reserves reached $20.9M.ALAH2 2025